A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma

Yanagihara, Ryan T.; Tom, Elysse S; Seitzman, Gerami D.; Saraf, Steven S.

doi:10.1080/09273948.2021.1928714

Cited by 9 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Moreover, in another report, a patient who developed uveitis while being treated with two BRAF/MEKi had a history of prior use of ICIs. 3 To our knowledge, this is the first case report of treatment with two BRAF/MEKi and subsequent ICI causing uveitis.…”

Section: E T T E R T O T H E E D I T O R a Case Of Melanoma Complicat...mentioning

confidence: 75%

“…4 MEK inhibitors can directly damage the retina and disrupt the blood-retinal barrier by affecting the retinal pigment epithelium and photoreceptor cells, thereby increasing their permeability. 3 In addition, HLA-DR4 is a known genetic risk factor for VKHD, and some cases of BRAF/MEKi and ICI-associated uveitis that were HLA-DR4 positive have been reported, suggesting its involvement. 5 In conclusion, this case of uveitis was caused by both BRAF/MEKi and ICI, with HLA-DR4 positivity considered a contributing factor.…”

Section: Although the Mechanism Of Uveitis Induction By Icis And Braf/mentioning

confidence: 99%

See 1 more Smart Citation

A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment

Obaru,

Kimura,

Yamamura

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Section: E T T E R T O T H E E D I T O R a Case Of Melanoma Complicat...mentioning

confidence: 75%

Section: Although the Mechanism Of Uveitis Induction By Icis And Braf/mentioning

confidence: 99%

A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment

Obaru,

Kimura,

Yamamura

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

“…The above mechanisms may be involved in the pathogenesis of autoimmune diseases, including small vessel vasculitis,6 7 dermatomyositis,8 pneumonitis,9 glomerulonephritis,10 panniculitis,11 12 interstitial nephritis13 and ocular inflammatory complications14–18 (table 1), which have been reported as adverse events of BRAF and MEK inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma

Ichikawa,

Ohno,

Kubo

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

The combination therapy of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors is approved for treating patients with BRAF V600E-positive tumours, including melanoma and lung cancer. Several case reports indicated autoimmune side effects associated with the use of BRAF and MEK inhibitors. Still, the effects of these drugs on the immune system were not fully elucidated. Here, we report a patient with large-vessel vasculitis diagnosed after initiation of treatment with dabrafenib and trametinib for BRAF V600E-positive metastatic lung adenocarcinoma. She was a never-smoker woman in her early 70s who presented with a chronic cough and was diagnosed with BRAF V600E-positive metastatic lung adenocarcinoma by transbronchial lung biopsy. She was successfully treated with prednisolone and methotrexate while BRAF and MEK inhibitors were continued. We should be careful about autoimmune diseases using BRAF and MEK inhibitors.

show abstract

“…[84][85][86][87][88][89][90][91][92] Yakın zamanda Yanagihara ve ark. [93] BRAF-mutant metastatik melanom tanısıyla 2 aydır dabrafenib/trametinib tedavisi almakta olan 32 yaşındaki bir olguda, bilateral anterior üveit ve multifokal koroidit geliştiğini bildirmişlerdir. İlaçların kesilmesi ve subtenon steroid uygulanması ile aktif üveitin hızla gerilediği fakat arka kutupta yaygın koryoretinal skar odakları geliştiğini belirtilmiştir.…”

Section: Melanom Için Hedefe Yönelik İlaç Tedavileriunclassified

Drugs Causing Uveitis: Pathogenesis, Diagnosis and Treatment

2023

Güncel Retina (Current Retina)

View full text Add to dashboard Cite

Drug-induced uveitis, which may result from systemic, periocular, intraocular, and topical application of certain drugs, has been covered extensively in numerous publications over the last decade. The dose and duration of the drug and other drugs used simultaneously may be determinative in the development of the uveitis. Drug-induced uveitis, which is rare and can occur in a wide clinical spectrum from mild to severe, usually regresses rapidly with accurate diagnosis and discontinuation of the relevant drug. Therefore, it is important for clinicians to be aware of the drugs that cause uveitis.

show abstract

A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma

Cited by 9 publications

References 18 publications

A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment

A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment

Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma

Drugs Causing Uveitis: Pathogenesis, Diagnosis and Treatment

Contact Info

Product

Resources

About